Amgen Inc
USUSDAmgen Inc (MX:AMGN) — Biotechnology: Biological Products (No Diagnostic Substances). Liczba giełd, na których notowane są akcje spółki: 4. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.
O firmie
- Strona
- amgen.com
- Relacje inwestorskie
- investors.amgen.com/
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siedziba
- Thousand Oaks, United States
- Prezes
- Robert A. Bradway
- Pracownicy
- 17 900
- Założona
- 1980
- Notowana od
- 29.02.2008 (MX:AMGN)
- Akcje w obrocie
- 540.63 mln na 2026-07-30
- Free float
- 539.16 mln
- Kapitalizacja rynkowa
- 226.05 mld USD
- Insiderzy
- 0.23%
- Inwestorzy instytucjonalni
- 85.02%
- Branża (SIC)
- Biological Products, (No Diagnostic Substances)
- Forma prawna
- XTIQ
- ISIN
- US0311621009
- LEI
- 62QBXGPJ34PQ72Z12S66
- Stopa wypłaty
- 60.4%
- FCF
- 10.2 mld USD52%
- Dług
- 57.3 mld USD4.3 l. FCF
- Staż dywidendowy
- 15 l.
- Zysk, FCF i wypłacone dywidendy — za 12 miesięcy do 30.06.2026 (najnowszy raport spółki).
Opis
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Giełdy i tickery
| Giełda | Ticker | Waluta | Cena | Typ |
|---|---|---|---|---|
| US USA Stocks | AMGN główne | USD | 407.44 -1.37% | akcje zwykłe |
| HK Hong Kong Stock Exchange | 4332 dodatkowe | HKD | — | |
| LSE London Stock Exchange | 0R0T IOB | USD | 411.854 +1.17% | akcje zwykłe |
| MX Mexican Stock Exchange | AMGN dodatkowe | MXN | 7 500.0098 +0.00% | akcje zwykłe |
| XETRA Xetra | AMG dodatkowe | EUR | 367.95 -1.39% | akcje zwykłe |
Dywidendy
Amgen Inc (AMGN) wypłaca dywidendy kwartalnie. Per year (12 months up to and including the latest announced payment): 180.7291 MXN per share (payments: 4). To około 2.41% obecnej ceny akcji. Na podstawie historii wypłat następna data ex-dywidendy spodziewana jest około 20.11.2026. Lata nieprzerwanych dywidend: 15.
| Dzień ex | Wypłata | Kwota | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-08-21 | — | 45.8186 MXN | 0.6/2.4 % | kwartalnie | MX:AMGN |
| 2026-05-15 | — | 45.8186 MXN | 0.6/2.4 % | kwartalnie | MX:AMGN |
| 2026-02-13 | — | 45.8186 MXN | 0.6/2.3 % | kwartalnie | MX:AMGN |
| 2025-11-21 | — | 43.2732 MXN | 0.6/2.3 % | kwartalnie | MX:AMGN |
| 2025-08-22 | — | 43.2732 MXN | 0.6/2.3 % | kwartalnie | MX:AMGN |
| 2025-05-16 | — | 43.2732 MXN | 0.6/2.2 % | kwartalnie | MX:AMGN |
| 2025-02-14 | — | 43.2732 MXN | 0.6/2.2 % | kwartalnie | MX:AMGN |
| 2024-11-19 | — | 40.9095 MXN | 0.5/2.2 % | kwartalnie | MX:AMGN |
| 2024-08-16 | — | 40.9095 MXN | 0.5/2.2 % | kwartalnie | MX:AMGN |
| 2024-05-16 | — | 40.9095 MXN | 0.5/2.1 % | kwartalnie | MX:AMGN |
| 2024-02-15 | — | 40.9095 MXN | 0.5/2.1 % | kwartalnie | MX:AMGN |
| 2023-11-16 | — | 38.7277 MXN | 0.5/2.1 % | kwartalnie | MX:AMGN |
| 2023-08-17 | — | 38.7277 MXN | 0.5/2.0 % | kwartalnie | MX:AMGN |
| 2023-05-17 | — | 38.7277 MXN | 0.5/2.0 % | kwartalnie | MX:AMGN |
| 2023-02-14 | — | 38.7277 MXN | 0.5/1.9 % | kwartalnie | MX:AMGN |
| 2022-11-16 | — | 35.2731 MXN | 0.5/1.9 % | kwartalnie | MX:AMGN |
| 2022-08-17 | — | 35.2731 MXN | 0.5/1.8 % | kwartalnie | MX:AMGN |
| 2022-05-16 | — | 35.2731 MXN | 0.5/1.4 % | kwartalnie | MX:AMGN |
| 2022-02-14 | — | 35.2731 MXN | 0.5/0.9 % | kwartalnie | MX:AMGN |
| 2021-11-16 | — | 32.0003 MXN | 0.4/0.4 % | kwartalnie | MX:AMGN |
Najwięksi akcjonariusze
| Posiadacz | Udział | Akcje | Data raportu |
|---|---|---|---|
| Blackrock Inc. | 9.13% | 49.36 mln | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 35.25 mln | 2026-06-30 |
| State Street Corporation | 5.65% | 30.56 mln | 2026-06-30 |
| Capital World Investors | 5.38% | 29.08 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 17.13 mln | 2026-06-30 |
| Invesco Ltd. | 3.02% | 16.32 mln | 2026-06-30 |
| Geode Capital Management… | 2.9% | 15.7 mln | 2026-06-30 |
| Charles Schwab Investmen… | 2.78% | 15.03 mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 14.85 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 13.99 mln | 2026-06-30 |
| Morgan Stanley | 2.53% | 13.65 mln | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 11.61 mln | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.81% | 9.79 mln | 2026-05-31 |
| Income Fund of America | 1.44% | 7.76 mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 7.28 mln | 2026-07-31 |
| Wells Fargo & Company | 1.34% | 7.24 mln | 2026-06-30 |
| AMERICAN BALANCED FUND | 1.31% | 7.09 mln | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 6.98 mln | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 6.6 mln | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.16% | 6.27 mln | 2026-06-30 |
| BRADWAY ROBERT A (Chief… | ≈0.12% | 657 299 | 2026-05-05 |
| SANTOS ESTEBAN (Officer) | ≈0.02% | 84 279 | 2026-05-05 |
| GORDON MURDO (Officer) | ≈0.01% | 51 837 | 2026-05-05 |
| GRIFFITH PETER H. (Chief… | ≈0.01% | 50 706 | 2026-05-05 |
| REESE DAVID M. (Chief Te… | ≈0.01% | 42 812 | 2026-05-05 |
| GRAHAM JONATHAN P (Gener… | ≈0.01% | 40 211 | 2026-05-05 |
| BRADNER JAMES E. (Office… | ≈0.01% | 30 462 | 2026-05-05 |
| ECKERT ROBERT ANDREW (Di… | ≈0% | 26 251 | 2026-05-19 |
| JACKS TYLER (Director) | ≈0% | 18 284 | 2026-05-19 |
| KULLMAN ELLEN JAMISON (D… | ≈0% | 14 536 | 2026-05-19 |
